Jack Allen

Stock Analyst at Baird

(1.52)
# 3,469
Out of 5,043 analysts
41
Total ratings
41.18%
Success rate
-8.16%
Average return
Main Sectors:
Top Industries:

Stocks Rated by Jack Allen

Vor Biopharma
Oct 15, 2025
Upgrades: Outperform
Price Target: $20$64
Current: $27.19
Upside: +135.38%
Taysha Gene Therapies
Oct 2, 2025
Maintains: Outperform
Price Target: $7$12
Current: $4.75
Upside: +152.63%
Fate Therapeutics
May 14, 2025
Maintains: Neutral
Price Target: $5$4
Current: $1.65
Upside: +142.42%
Allogene Therapeutics
May 14, 2025
Maintains: Outperform
Price Target: $12$9
Current: $1.20
Upside: +650.00%
MiNK Therapeutics
Nov 15, 2024
Maintains: Outperform
Price Target: $80$40
Current: $14.98
Upside: +167.11%
Arcellx
Nov 6, 2024
Maintains: Outperform
Price Target: $77$106
Current: $84.68
Upside: +25.18%
Intellia Therapeutics
Oct 25, 2024
Maintains: Neutral
Price Target: $24$18
Current: $25.60
Upside: -29.69%
Instil Bio
Sep 16, 2024
Reiterates: Outperform
Price Target: $180
Current: $19.40
Upside: +827.84%
Mereo BioPharma Group
Jun 13, 2024
Initiates: Outperform
Price Target: $8
Current: $2.00
Upside: +300.00%
CRISPR Therapeutics AG
May 9, 2024
Maintains: Neutral
Price Target: $46$52
Current: $67.61
Upside: -23.09%
Initiates: Outperform
Price Target: $84
Current: $33.18
Upside: +153.16%
Initiates: Outperform
Price Target: $5
Current: $1.70
Upside: +194.12%
Upgrades: Outperform
Price Target: n/a
Current: $3.48
Upside: -
Upgrades: Outperform
Price Target: $6$9
Current: $4.65
Upside: +93.55%